From Snapshots to Movies
Long-acting Injectable Formulations
Two Acts, One Geopolitical Moment
AI is in Every Pharma Strategy Deck
Could a Formal Trust Coefficient Release the Pharmacovigilance Capacity AI Promised
EDITORIAL SECTIONS
RESEARCH & DEVELOPMENT
Adopting the Power of AI to Drug Development Projects
A tremendous amount of documentation is created throughout the clinical trial lifecycle
CLINICAL TRIALS
Real-world Evidence
Hearing the diagnosis from the doctor that your child has spinal muscular atrophy SMA
MANUFACTURING
Just in Time Manufacturing Creating more sustainable supply chains
Drug development has transformed immeasurably over the past decade Even before the Covid pandemic and the conflict in Ukraine
Information Technology
Challenges and Advantages of Using Artificial Intelligence in Pharma
Many advanced largescale AI initiatives still need to be proved successful in Pharma
KNOWLEDGE BANK
Interviews
Ensuring Ethics in AI-Driven Drug Safety
Senior Director of Pharmacovigilance and Risk Management at Curis Inc.
Ashish Jain is Senior Director of Pharmacovigilance and Risk Management at Curis Inc with over years of experience in drug safety He is also leading the Innovation Working Group at the North American Society of Pharmacovigilance NASoP his expertise in combining technological innovation with patient safety makes him uniquely qualified to address the ethical challenges of AI implementation in pharm...
Articles
A Structured Review on BCRP-Mediated Multidrug Resistance
Many of the human ABC proteins are efflux transporters and three of them namely Pglycoprotein Pgp gene symbol ABCB the multidrug resistance protein MRP gene symbol ABCC and the breast cancer resistance protein BCRP gene symbol ABCG have been implicated to be the major efflux transporters responsible for multidrug resistance in cancer cells
Research Insights
Validated Spectrometric Determination Of Penciclovir And Entecavir In Bulk And In Pharmaceutical Preparations
Abstract Simple rapid and sensitive spectroscopic methods were developed and validated for the determination of antiviral agents namely penciclovir PCV and entecavir ETV The first method is based on measuring the native fluorescence of each of the cited drugs at its optimum excitation and emission wavelengths The fluorescence intensity was measured for PCV
Case Studies
Impact Of Substitution Among Generic Drugs On Persistence And Adherence:a Retrospective Claims Data Case Study
Abstract Once the period of exclusivity on a reference medicine expires it is possible to apply for marketing of a generic version of that medicine By definition a generic product is considered interchangeable with the innovator brand product when it demonstrates the same qualitative and quantitative composition in active substances the same pharmaceutical form and bi...
Techno Trends
MannKind Introduces First-and-Only Afrezza® Therapy for Treating Diabetes in Children and Adolescents
MannKind has introduced Afrezza for the treatment of diabetes in children and adolescents aged six years and older requiring mealtime insulin therapy
White Papers
Cloud Computing in the Laboratory Informatics Solutions and Validation Approaches
In the modern business environment, a significant portion of work is conducted using computerized systems. Many solutions are used to complete tasks, including simple desktop programs like email and Microsoft Office to enterprise-wide, global systems like ERP (Enterprise Resource Planning), MES (Manufacturing Execution System), and LIMS
TOP ARTICLES
The Potential of Cell Free Chromatin Inhibition in Cancer
Divya Mishra is a board certified oncologist with over 17 years’ experience in the pharmaceutical/CRO industry, clinical practice, and academia, in areas of oncology/haematology, family medicine, palliative medicine, and outcomes research. Mishra has worked across multiple geographies and diverse, multicultural settings for organisations such as Pfizer, IQVIA, and SFJ. She is currently working at ICON as a medical director and therapeutic expert for the oncology/haematology disease areas in the APAC region, based in the regional headquarters in Singapore.
Machine Learning for New Drugs
Sneha Rai completed her Ph.D. from Computational and Structural Biology Lab., Department of Biological Sciences and Engineering at Netaji Subhas Institute of Technology (DU). She did masters in Bioinformatics from Banaras Hindu University and holds six years of bioinformatics research experience. Her area of interest includes structural bioinformatics, systems biology, protein/gene network analysis, data mining, computer aided drug designing, computational genomics, NGS data analysis, variant analysis and their clinical interpretation.
Venugopal Bhatia graduated from NSIT in 2019 with a B.E. in Biotechnology. During his undergraduate studies he was involved as an undergraduate researcher at the Computational and Structural Biology Laboratory and worked on two projects which were later published in Nature Scientific Reports and Elsevier Computational Biology and Chemistry. After a brief stint in industry, he's now pursuing his Master's at Yale.
Sonika Bhatnagar, Ph.D. (Biophysics), AIIMS works in the broad area of computational molecular biology. Her laboratory uses techniques of drug target selection, drug design & discovery, machine learning, and integrative genomics & proteomics towards Cardiovascular disease drug design and infectious disease therapeutics.
Beyond the Cold Chain
Dr. Mary Manoranjani Addanki, PhD, is an Associate Professor and Head of Pharmaceutics at Malla Reddy College of Pharmacy. With 17 years of expertise, she specialises in nanotechnology, pulmonary vaccines, and advanced drug delivery. An award-winning researcher and patent holder, her work focuses on stabilising vaccines and developing innovative dosage forms.
The Role of Technology in Continued Process Verification 4.0
Dr. Kavita is a seasoned leader in the field of data and insights, with over 20 years of invaluable experience. She is a result-oriented solution designer in data warehouse and big data analytics. Drawing from her extensive in multinational organisations IBM, Capgemini, and others, Kavita has successfully overseen numerous large and intricate projects. Her expertise lies in effectively leveraging her robust technical knowledge in areas such as data warehousing and business intelligence to drive impactful outcomes. Under Dr. Kavita's exceptional leadership, the CaliberAPQR product has achieved outstanding recognition.
Transforming Customer Engagement in Life Sciences Adopting Hybrid Commercial Models (HCMs)
is a Practice Director at the Life Sciences IT Services team, leading commercial technology research and client engagements. He has worked with business and IT leaders on strategy, M&A, and market intelligence. Previously a Consultant at EY, Rohit holds an MBA from FMS, Delhi University, and an engineering degree from NIT Jalandhar.
press releasesRead more...
Telix and Ekalia to Collaborate on Astatine-211 Production in the U.S.
Telix and Ekalia a joint venture between IBA Ion Beam Applications SA EURONEXT and Framatome today announced a collaboration to advance scalable United States US production of astatine At an alphaemitting radioisotope being investigated for targeted alpha therapy
HistoIndex and A*STAR Partner To Advance Early – Stage Development Of Pipeline Therapies For Fibrotic Diseases
HistoIndex a pioneer in AIdriven digital pathology for fibrotic diseases and the Agency for Science Technology and Research ASTAR Singapores lead public sector RD agency have signed a Memorandum of Understanding MoU to collaborate on the preclinical evaluation
Cotecna Group Acquires Energon Labs
Cotecna a leading provider of Testing Inspection and Certification TIC services today announced the acquisition of Energon Labs a cGMPcompliant USFDAinspected ISO and ISO certified analytical testing laboratory based in Hyderabad India
Waters Launches AI Link, Advancing AI-Enabled LC-MS Workflows from Research to Release
Waters Corporation announced that it has launched Waters AI Link a software capability that brings Anthropics Model Context Protocol MCP to its informatics platform and has joined Anthropics Model Hardware Standard MHS research program
Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 1
Takeda announced that ORZEYFUL oveporexton is now available in Japan and China for the treatment of narcolepsy type NT providing first access to clinicians to prescribe treatment with the new class of medicine ORZEYFUL is a firstinclass orexin receptor OXR agonist in tablet form designed to treat...
Merck Inaugurates State-of-the-Art ADVANCE Bioanalytical Facility on West Point, Pennsylvania, Campus
Merck known as MSD outside of the United States and Canada today inaugurated its stateoftheart ADVANCE research facility on its West Point Pennsylvania campus signaling a new chapter in global scientific discovery Pennsylvania Gov Josh Shapiro joined Merck executive leadership federal and state gove...
EventsRead more...
21 - 23
Oct 2026Drug Formulation & Drug Delivery 2026
Paris, France
21 - 22
Oct 2026Advance Clinical Trials and Research 2026
Paris, France
22 - 23
Oct 2026PDA Aseptic Symposium 2026
Congress Square Nakanoshima, O...
26 - 28
Oct 2026ACHEMA Middle East 2026
RICEC, Riyadh, KSA, Saudi Arab...
26 - 28
Oct 2026World Orphan Drug Congress
RAI, Amsterdam, Netherlands
27 - 28
Oct 2026PM& AC 2026
Novotel Hyderabad Convention C...
28 - 30
Oct 2026BIOPLUS-INTERPHEX KOREA 2026
COEX, Seoul
02 - 04
Nov 2026Pharma Forum EMEA 2026
Dom Pedro Lisboa Hotel, Lisbon...
LATEST NEWSRead more...
UCB Receives Approval for ZILBRYSQ Autoinjector for Adults with Generalised Myasthenia Gravis
UCB has received approval from the US Food and Drug Administration FDA for a new autoinjector option for ZILBRYSQ zilucoplan a treatment for adults with generalised myasthenia gravis gMG who test positive for antiacetylcholine receptor AChR antibodies
Nxera Pharma Partners with Synmosa to Commercialise QUVIVIQ
Nxera Pharma has entered into an exclusive licensing supply and commercialisation agreement with Synmosa Biopharma to expand access to QUVIVIQ daridorexant a medicine used to treat insomnia across eight AsiaPacific markets QUVIVIQ was discovered and developed by Idorsia Pharmaceuticals
Vir Biotechnology Enters into Collaboration with Gilead Sciences to Develop T-cell Engagers for Solid Tumours
Vir Biotechnology has entered into a collaboration and licensing agreement with Gilead Sciences to discover and develop three novel Tcell engager TCE candidates for the treatment of solid tumours Tcell engagers are designed to direct T cells a type of immune cell towards cancer cells and help destro...
Zealand Pharma Enters into Collaboration with Generate Biomedicines on AI-Designed Protein Therapies for Metabolic Diseases
Zealand Pharma and Generate Biomedicines have entered into a multitarget collaboration and licensing agreement to develop proteinbased treatments for obesity and other metabolic diseases using artificial intelligence AI The collaboration will combine Zealand Pharmas expertise in metabolic diseases w...
Enodia Therapeutics Enters into Collaboration with Pfizer to Develop Small-Molecule Sec61 Inhibitors
Enodia Therapeutics has entered into a research collaboration and licensing agreement with Pfizer to discover and develop smallmolecule inhibitors targeting Sec a protein complex involved in the movement of newly formed proteins across cell membranes
InnoCare Announces Approval of Clinical Trial of Bispecific Antibody ICP-B161 Targeting TL1A and IL-23p19 in China
InnoCare Pharma a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases announced today that the Center for Drug Evaluation CDE of Chinas National Medical Products Administration NMPA has approved its Investigational New Drug IND application for ICPB a bispeci...
